GENETIC · Unmapped registry intervention
Sequencing of ctDNA in plasma
Find medicine records ·
Find other trials using this name
Clinical trial
Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With Advanced Lung Adenocarcinoma
NCT03090815
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedCirculating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With Advanced Lung Adenocarcinoma
Design: OBSERVATIONAL · Status: UNKNOWN · Phase: Not specified
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Adenocarcinoma of Lung (Disorder)unresolved
Interventions
Sponsors & collaborators
The University of Hong Konglead sponsor
Feinstein Institute for Medical Researchcollaborator
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03090815 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.